GUTS
Fractyl Health, Inc. (GUTS) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | C- (1.9) | F (0.5) | F (0.5) | C+ (2.6) | D+ (1.6) |
| 2026-11-05 | C+ (2.5) | C- (1.9) | F (0.5) | F (0.6) | C+ (2.7) | D+ (1.6) |
| 2026-10-29 | C+ (2.5) | C- (1.9) | F (0.6) | D- (1.1) | C+ (2.7) | D+ (1.7) |
| 2026-10-22 | C+ (2.5) | D+ (1.6) | F (0.6) | D- (1.1) | C+ (2.6) | D+ (1.7) |
| 2026-10-15 | C+ (2.5) | D (1.4) | F (0.6) | D+ (1.5) | C+ (2.6) | D+ (1.7) |